Moorestown, NJ, September 19, 2019 – Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today announced the following platforms, infrastructure and locations meet the HITRUST CSF v9.2 certification criteria for information security by HITRUST: Tabula Rasa HealthCare – MedWise™, NiaRx-MedWise University Edition and EireneRx®, – their supporting infrastructure and corporate locations (Moorestown, NJ, Mount Pleasant, SC and Boulder CO, and nationwide).
HITRUST CSF Certification status demonstrates that the organization’s technology products and solutions MedWise, MedWise University Edition and EireneRx have met key regulations and industry-defined requirements and is appropritely managing risk. This achievement places TRHC in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards and frameworks, and incorporating a risk-based approach, the HITRUST CSF helps organizations address these challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.
“TRHC is committed to meeting the challenge of complex compliance requirements that include technical and process elements such as HIPAA, NIST, ISO and COBIT,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “The HITRUST CSF is the gold-standard that needs to be met, and TRHC is pleased to be able to demonstrate its commitment by achieving HITRUST CSF Certification. TRHC is committed to protecting the privacy of our clients and their patients and members we serve.”
“HITRUST has been working with the industry to ensure the appropriate information protection requirements are met when sensitive data is accessed or stored in a cloud environment. By taking the steps necessary to obtain HITRUST CSF Certified status, TRHC is distinguished as an organization that people can count on to keep their information safe,” said Ken Vander Wal, Chief Compliance Officer, HITRUST.
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 1, 2019, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website http://ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.